Last reviewed · How we verify
Ocrelizumab Dose 1
Ocrelizumab Dose 1 is a CD20-targeting monoclonal antibody Small molecule drug developed by Genentech, Inc.. It is currently in Phase 3 development for Relapsing-remitting multiple sclerosis, Primary progressive multiple sclerosis.
Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation.
Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation. Used for Relapsing-remitting multiple sclerosis, Primary progressive multiple sclerosis.
At a glance
| Generic name | Ocrelizumab Dose 1 |
|---|---|
| Sponsor | Genentech, Inc. |
| Drug class | CD20-targeting monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Ocrelizumab targets CD20, a surface antigen expressed on B cells, leading to B cell depletion through antibody-dependent cellular cytotoxicity and direct induction of apoptosis. By eliminating B cells, the drug reduces the production of autoantibodies and pro-inflammatory cytokines, thereby suppressing the autoimmune response underlying multiple sclerosis and other B cell-mediated conditions.
Approved indications
- Relapsing-remitting multiple sclerosis
- Primary progressive multiple sclerosis
Common side effects
- Infusion-related reactions
- Upper respiratory tract infections
- Lower respiratory tract infections
- Headache
- Fatigue
Key clinical trials
- Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (PHASE3)
- Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PHASE3)
- Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab (PHASE4)
- A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (PHASE3)
- A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) (PHASE3)
- PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ocrelizumab Dose 1 CI brief — competitive landscape report
- Ocrelizumab Dose 1 updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI
Frequently asked questions about Ocrelizumab Dose 1
What is Ocrelizumab Dose 1?
How does Ocrelizumab Dose 1 work?
What is Ocrelizumab Dose 1 used for?
Who makes Ocrelizumab Dose 1?
What drug class is Ocrelizumab Dose 1 in?
What development phase is Ocrelizumab Dose 1 in?
What are the side effects of Ocrelizumab Dose 1?
What does Ocrelizumab Dose 1 target?
Related
- Drug class: All CD20-targeting monoclonal antibody drugs
- Target: All drugs targeting CD20
- Manufacturer: Genentech, Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Relapsing-remitting multiple sclerosis
- Indication: Drugs for Primary progressive multiple sclerosis
- Compare: Ocrelizumab Dose 1 vs similar drugs
- Pricing: Ocrelizumab Dose 1 cost, discount & access